Equity Details
Price & Market Data
Price: $4.54
Daily Change: +$0.02 / 0.44%
Daily Range: $4.47 - $4.75
Market Cap: $7,534,638
Daily Volume: 9,960
Performance Metrics
1 Week: 3.65%
1 Month: 5.34%
3 Months: -54.76%
6 Months: -86.78%
1 Year: -78.99%
YTD: -84.01%
About BioAtla, Inc. (BCAB)
Get insights into BioAtla, Inc. (BCAB)'s financial health. With a price of 4.54, the stock shows a +$0.02 / 0.44% daily change. Its market cap is 7,534,638. Detailed performance for 1-month (5.34%) and 52-week (-78.99%) periods are crucial.
Company Details
Employees: 41
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.